sr141716 has been researched along with Fibrosarcoma in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bifulco, M; D'Alessandro, A; Galgani, M; Gazzerro, P; Laezza, C; Malfitano, AM; Matarese, G | 1 |
Croft, DL; Hamamoto, DT; Kehl, LJ; Norsted, BD; Simone, DA; Wacnik, PW; Wilcox, GL | 1 |
2 other study(ies) available for sr141716 and Fibrosarcoma
Article | Year |
---|---|
The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Ascites; Cell Cycle; Cell Line, Tumor; Cell Survival; Female; Fibrosarcoma; Gene Expression Regulation, Neoplastic; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sarcoma | 2012 |
A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain.
Topics: Animals; Benzoxazines; Calcium Channel Blockers; Camphanes; Cannabinoids; Carrageenan; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Fibrosarcoma; Haloperidol; Hand Strength; Humerus; Hyperalgesia; Male; Mice; Mice, Inbred C3H; Morpholines; Myositis; Naphthalenes; Neoplasm Transplantation; Neoplasms; Pain; Piperidines; Psychomotor Performance; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2003 |